CMPS

COMPASS Pathways plc [CMPS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CMPS Stock Summary

Top CMPS Correlated Resources

CMPS


Top 10 Correlated ETFs

CMPS


Top 10 Correlated Stocks

CMPS


In the News

02:46 22 Mar 2023 CMPS

COMPASS Pathways earns repeat ‘Buy' rating and US$60 price target on adjusted trial design for COMP360

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy' rating and US$60 price target for COMPASS Pathways after the mental health care company adjusted the trial design for its COMP360 phase 3 program investigating psilocybin for treatment-resistant depression (TRD).   “We are not making any major changes to our model post-4Q22 results,” the analysts wrote in a note to clients.

08:30 22 Mar 2023 CMPS

2 Growth Stocks With Incredible Potential in the Next 5 Years

Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.

10:23 22 Mar 2023 CMPS

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows:

12:01 22 Mar 2023 CMPS

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023

Conference call to be held at 8:00am ET (1:00pm UK) Conference call to be held at 8:00am ET (1:00pm UK)

05:52 22 Mar 2023 CMPS

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street

These stocks are risky. But they just might deliver huge gains if analysts are right.

08:28 22 Mar 2023 CMPS

7 Tempting Sin Stocks to Buy for Promising Profits

Following a rough year, investors seeking positive returns might want to consider going a bit controversial with sin stocks. Understandably, with the political winds turning progressive, people nowadays turn a stink eye toward cynicism.

02:30 22 Mar 2023 CMPS

The 7 Most Promising Psychedelic Stocks to Buy in February

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

11:45 22 Mar 2023 CMPS

Psychedelic Sunday: Competitive Strategies

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

01:33 22 Mar 2023 CMPS

All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy

COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11:17 22 Mar 2023 CMPS

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.

CMPS Financial details

Company Rating
Neutral
Market Cap
356.22M
Income
-91.51M
Revenue
0
Book val./share
4.27
Cash/share
3.37
Dividend
-
Dividend %
-
Employees
116
Optionable
No
Shortable
Yes
Earnings
28 Feb 2023
P/E
-4.33
Forward P/E
-
PEG
-2.09
P/S
-
P/B
2.18
P/C
2.77
P/FCF
-3.76
Quick Ratio
10.18
Current Ratio
12.29
Debt / Equity
0.09
LT Debt / Equity
0
-
-
EPS (TTM)
-2.16
EPS next Y
-
EPS next Q
-
EPS this Y
20.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
69.77%
-
-
-
-
SMA20
-8.93%
SMA50
7.59%
SMA100
-13.37%
Inst Own
17.86%
Inst Trans
0.28%
ROA
-46%
ROE
-43%
ROC
-0.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
42.76M
Shs Float
13.51M
-
-
-
-
Target Price
-
52W Range
6.54-21.5
52W High
-55.57%
52W Low
+55.5%
RSI
59.24
Rel Volume
1.16
Avg Volume
262.74K
Volume
304.04K
Perf Week
20.39%
Perf Month
-8.98%
Perf Quarter
-23.02%
Perf Half Y
-30.99%
-
-
-
-
Beta
2.46164
-
-
Volatility
0.38%, 0.61%
Prev Close
10.02%
Price
9.33
Change
12.68%

CMPS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-0.77-1.14-3.55-1.79-2.16
Operating cash flow per share
-0.57-1.03-2.44-1.69-2.48
Free cash flow per share
-0.58-1.04-2.44-1.7-2.5
Cash per share
1.331.4511.26.833.37
Book value per share
-0.83-1.7611.577.114.27
Tangible book value per share
-0.83-1.7611.577.114.27
Share holders equity per share
-0.83-1.7611.577.114.27
Interest debt per share
01.2200.090.05
Market cap
500.51M500.51M809.48M883.95M340.76M
Enterprise value
477.6M496.63M619.16M614.32M199.49M
P/E ratio
-37.86-25.52-13.42-12.32-3.72
Price to sales ratio
00000
POCF ratio
-51.07-28.1-19.56-13.05-3.23
PFCF ratio
-50.4-27.84-19.5-12.98-3.21
P/B Ratio
-34.83-16.474.123.111.88
PTB ratio
-34.83-16.474.123.111.88
EV to sales
00000
Enterprise value over EBITDA
-36.19-25.42-10.29-8.61-2.2
EV to operating cash flow
-48.73-27.88-14.96-9.07-1.89
EV to free cash flow
-48.09-27.62-14.92-9.02-1.88
Earnings yield
-0.03-0.04-0.07-0.08-0.27
Free cash flow yield
-0.02-0.04-0.05-0.08-0.31
Debt to equity
-2.84-2.070.040.060.09
Debt to assets
1.541.940.030.050.08
Net debt to EBITDA
1.740.23.163.781.56
Current ratio
14.241.3529.3619.5512.29
Interest coverage
00000
Income quality
0.740.910.690.941.15
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.01000.01
Capex to revenue
00000
Capex to depreciation
-5.91-2.62-1.17-1.91-1.81
Stock based compensation to revenue
00000
Graham number
3.796.7130.416.9414.4
ROIC
0.621.120.290.341.18
Return on tangible assets
-0.5-0.61-0.3-0.24-0.46
Graham Net
-0.94-1.9611.056.633.27
Working capital
24.43M8.3M195.51M280.19M176.06M
Tangible asset value
-14.37M-30.39M196.56M284.41M181.28M
Net current asset value
-14.48M-30.61M195.51M278.81M175.64M
Invested capital
0-0.6900.010.01
Average receivables
03.68M5.5M8.5M13.42M
Average payables
01.01M2.04M2.66M3.66M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.920.65-0.31-0.25-0.5
Capex per share
-0.01-0.01-0.01-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
00000
Net income per share
-0.61-0.5-0.5-0.43-0.73
Operating cash flow per share
-0.53-0.55-0.42-0.45-1.07
Free cash flow per share
-0.54-0.55-0.43-0.45-1.07
Cash per share
6.535.84.884.073.37
Book value per share
6.86.175.294.584.27
Tangible book value per share
6.86.175.294.584.27
Share holders equity per share
6.86.175.294.584.27
Interest debt per share
0.090.070.070.050.05
Market cap
924.52M541.85M459.58M456.3M340.76M
Enterprise value
654.9M301.16M255.39M285.48M199.49M
P/E ratio
-9.01-6.4-5.46-6.21-2.75
Price to sales ratio
00000
POCF ratio
-41.33-23.43-25.53-23.99-7.52
PFCF ratio
-41.16-23.35-24.95-24-7.5
P/B Ratio
3.252.092.052.351.88
PTB ratio
3.252.092.052.351.88
EV to sales
00000
Enterprise value over EBITDA
-25.68-14.36-12.23-15.72-6.49
EV to operating cash flow
-29.28-13.02-14.18-15.01-4.4
EV to free cash flow
-29.16-12.98-13.87-15.01-4.39
Earnings yield
-0.03-0.04-0.05-0.04-0.09
Free cash flow yield
-0.02-0.04-0.04-0.04-0.13
Debt to equity
0.060.050.060.150.09
Debt to assets
0.050.050.060.130.08
Net debt to EBITDA
10.5711.479.789.44.6
Current ratio
19.5522.8217.537.412.29
Interest coverage
00000
Income quality
0.871.090.861.041.46
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
000.0200
Capex to revenue
00000
Capex to depreciation
-1.79-1.52-4.430-1.11
Stock based compensation to revenue
00000
Graham number
9.688.367.686.678.37
ROIC
0.110.120.150.180.34
Return on tangible assets
-0.09-0.08-0.09-0.08-0.16
Graham Net
6.345.744.853.693.27
Working capital
280.19M254.87M218.76M188.92M176.06M
Tangible asset value
284.41M259.57M224.59M194.56M181.28M
Net current asset value
278.81M254.03M217.94M188.49M175.64M
Invested capital
0.010.010.010.010.01
Average receivables
9.64M12.41M15.28M17.54M16.87M
Average payables
2.65M2.31M2.7M11.62M12.32M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.09-0.08-0.09-0.09-0.17
Capex per share
00-0.0100

CMPS Frequently Asked Questions

What is COMPASS Pathways plc stock symbol ?

COMPASS Pathways plc is a GB stock and trading under the symbol CMPS

What is COMPASS Pathways plc stock quote today ?

COMPASS Pathways plc stock price is $9.33 today.

Is COMPASS Pathways plc stock public?

Yes, COMPASS Pathways plc is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap